PL2329848T5 - Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 - Google Patents

Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Info

Publication number: PL2329848T5
Authority: PL; Poland
Prior art keywords: lixisenatide; metformin; diabetes; therapy; add
Prior art date: 2009-11-13

Application number

PL09175877T

Other languages

English (en)

Other versions

PL2329848T3 (pl

Inventor

Louise Silvestre

Elisabeth Souhami

Xiaodan Wei

Original Assignee

Sanofi-Aventis Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-13

Filing date

2009-11-13

Publication date

2019-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41800749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2329848(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-13 Application filed by Sanofi-Aventis Deutschland Gmbh filed Critical Sanofi-Aventis Deutschland Gmbh

2013-05-31 Publication of PL2329848T3 publication Critical patent/PL2329848T3/pl

2019-12-31 Publication of PL2329848T5 publication Critical patent/PL2329848T5/pl

Links

108010057186 Insulin Glargine Proteins 0.000 title 1
COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 title 1
XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 title 1
229960002869 insulin glargine Drugs 0.000 title 1
229960001093 lixisenatide Drugs 0.000 title 1
108010004367 lixisenatide Proteins 0.000 title 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title 1
229960003105 metformin Drugs 0.000 title 1
238000002560 therapeutic procedure Methods 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Immunology (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09175877T 2009-11-13 2009-11-13 Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 PL2329848T5 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09175877.1A EP2329848B2 (en)	2009-11-13	2009-11-13	Lixisenatide as add-on therapy to insulin glargine and metformin for treating type 2 diabetes

Publications (2)

Publication Number	Publication Date
PL2329848T3 PL2329848T3 (pl)	2013-05-31
PL2329848T5 true PL2329848T5 (pl)	2019-12-31

Family

ID=41800749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09175877T PL2329848T5 (pl)	2009-11-13	2009-11-13	Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2

Country Status (11)

Country	Link
EP (1)	EP2329848B2 (pl)
CY (1)	CY1113755T1 (pl)
DK (1)	DK2329848T4 (pl)
ES (1)	ES2398012T5 (pl)
HR (1)	HRP20121029T4 (pl)
ME (1)	ME01546B (pl)
PL (1)	PL2329848T5 (pl)
PT (1)	PT2329848E (pl)
RS (1)	RS52629B2 (pl)
SI (1)	SI2329848T2 (pl)
SM (1)	SMT201300013B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
AU2012213435B2 (en) *	2011-02-02	2017-03-30	Sanofi-Aventis Deutschland Gmbh	Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX359329B (es) *	2011-10-28	2018-09-25	Sanofi Aventis Deutschland	Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
UA117480C2 (uk)	2013-04-03	2018-08-10	Санофі	Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
JP6438944B2 (ja) *	2013-06-17	2018-12-19	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	インスリングラルギン／リキシセナチド固定比率製剤
EP3229828B1 (en)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels

2009
- 2009-11-13 PL PL09175877T patent/PL2329848T5/pl unknown
- 2009-11-13 SI SI200930473T patent/SI2329848T2/sl unknown
- 2009-11-13 DK DK09175877.1T patent/DK2329848T4/da active
- 2009-11-13 RS RS20120571 patent/RS52629B2/sr unknown
- 2009-11-13 PT PT91758771T patent/PT2329848E/pt unknown
- 2009-11-13 EP EP09175877.1A patent/EP2329848B2/en active Active
- 2009-11-13 ES ES09175877T patent/ES2398012T5/es active Active
- 2009-11-13 ME MEP-2012-147A patent/ME01546B/me unknown
2012
- 2012-12-13 HR HRP20121029TT patent/HRP20121029T4/hr unknown
2013
- 2013-01-09 CY CY20131100022T patent/CY1113755T1/el unknown
- 2013-01-30 SM SM201300013T patent/SMT201300013B/xx unknown

Also Published As

Publication number	Publication date
SI2329848T1 (sl)	2013-02-28
RS52629B2 (sr)	2019-11-29
HRP20121029T4 (hr)	2019-10-18
EP2329848B1 (en)	2012-10-24
ES2398012T3 (es)	2013-03-13
HRP20121029T1 (hr)	2013-01-31
DK2329848T4 (da)	2019-09-09
EP2329848B2 (en)	2019-06-19
EP2329848A1 (en)	2011-06-08
SMT201300013B (it)	2013-03-08
CY1113755T1 (el)	2016-07-27
ES2398012T5 (es)	2020-02-26
PT2329848E (pt)	2013-01-23
SI2329848T2 (sl)	2019-10-30
PL2329848T3 (pl)	2013-05-31
RS52629B (sr)	2013-06-28
ME01546B (me)	2014-04-20
DK2329848T3 (da)	2013-02-04

Publication	Publication Date	Title
HRP20121029T1 (hr)	2013-01-31	Liksisenatid kao pomoä†na terapija uz inzulin glargin i metformin kod lijeäśenja dijabetesa tip 2
SI2324853T1 (sl)	2015-12-31	Liksisenatid kot dodatek metforminu pri zdravljenju sladkorne bolezni tipa 2
LT2707015T (lt)	2017-02-27	Liksisenatidas kaip papildoma bazaliniam insulinui terapija, esant 2 tipo diabetui
IL219945A (en)	2016-12-29	1-GLP history with dual transduction and use of it to prepare a drug for the treatment of diabetes
IL209887A0 (en)	2011-02-28	Treatment for diabetes in patients inappropriate for metformin therapy
IL212903A0 (en)	2011-07-31	Treatment of diabetes in patients with inadequate glycemic control despite metformin therapy comprising a dpp-iv inhibitor
IL250548B (en)	2019-03-31	Acetyl analogs of insulin that are resistant to protease and their use for the preparation of a drug for the treatment and prevention of diabetes
PT2707017E (pt)	2016-01-12	Lixisenatida e metformina para tratamento da diabetes tipo 2
SI2379100T1 (sl)	2015-02-27	Zdravljenje hiperglikemije z GLP-1
PL2133091T3 (pl)	2014-03-31	Kompozycje zawierające supramolekularne układy insuliny użyteczne do leczenia cukrzycy
PL2611458T3 (pl)	2017-02-28	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
EP2127665A4 (en)	2011-06-29	MEDICAL PREPARATION BASED ON EXENATIDE AND DALARGINE FOR THE TREATMENT OF PANCREATIC DIABETES
PT2459207E (pt)	2014-02-21	Composição farmacêutica para tratamento de condições médicas e um método para tratamento de distúrbios alimentares e doenças relacionadas
ZA201105094B (en)	2012-03-28	Combination of insulin with triazine derivatives and its use for treating diabetes
GB0919603D0 (en)	2009-12-23	Use of thymosin beta-4 for treatment of type II diabetes
EG25982A (en)	2012-11-18	Painless insulin injecting pen
ZA201008998B (en)	2012-07-25	Treatment for diabetes in patients inappropriate for metformin therapy
EG27140A (en)	2015-08-09	Preparation and characterization of metformin as insulin resistant reducing agents for type ii diabetes
ZA200909123B (en)	2010-09-29	Compounds with 7-member cycle and the pharmaceutical use thereof for preventing and treating diabetes and metabolism syndrome
GB0904271D0 (en)	2009-04-22	Treatment of diabetes and metabolic syndrome
GB0912906D0 (en)	2009-08-26	Treatment of diabetes and metabolic syndrome
GB0910904D0 (en)	2009-08-05	Treatment of diabetes and metabolic syndrome
SG10201601210YA (en)	2016-03-30	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
GB0802903D0 (en)	2008-03-26	Treatment of diabetes